Introduction
Despite the emerging therapeutic options, multiple myeloma (MM) remains an incurable disease in the vast majority of the patients, with a highly variable outcome in different MM subgroups. 1 This heterogeneity is due to factors intrinsic to the malignant plasma cell as well as due to host factors, which are biological determinants of outcome. In addition to the parameters included in the Durie and Salmon 2 staging system, several clinical and laboratory markers, such as b2-microglobulin (b2M), C-reactive protein, 3 plasma cell proliferative activity (plasma cell labeling index, cell cycle analysis by flow cytometry), 4 ,5 cytogenetics, 6, 7 bone marrow angiogenesis 8, 9 or circulating proteasomes 10 were adopted to define risk groups in MM. Although flow cytometry and cytogenetics provide prognostically important information, the broad application of these techniques may have limitations due to costs, standardization and availability. Recently, the International Staging System (ISS) including the two parameters b2M and albumin, which were selected based on the analysis of 10 750 patients referred to 17 study centers between 1981 and 2002, was proposed as a simple staging system for patients with newly diagnosed symptomatic MM. 11 Although this classification predicts outcome, some additional disease characteristics, which reflect myeloma biology or tumor-host interactions in the bone marrow microenvironment, may be useful to create a more accurate prognostic model.
Lytic bone disease is a hallmark of MM. 12 The imbalance in RANKL (receptor activator of nuclear factor kappaB ligand)-toosteoprotegerin ratio in the bone marrow microenvironment is a crucial mechanism leading to osteoclast activation. 13 The increased bone resorption can be measured by various collagen type-I degradation markers.
14 In various studies, it was shown that serum carboxy-terminal telopeptide of type-1 collagen (ICTP) is a sensitive and specific marker of increased bone resorption [15] [16] [17] and has a prognostic impact for overall survival (OS) in MM patients. 16, 18 In longitudinal studies, it was furthermore shown that ICTP had the highest predictive value for the progression of myeloma-induced bone disease in patients treated with standard chemotherapy 19 and that ICTP levels decrease in patients with MM under bisphosphonate treatment. 20 Recent studies demonstrated that bone markers, which reflect osteoclast and osteoblast activity, can be modulated by novel agents such as proteasome inhibitors or immunmodulatory drugs. [21] [22] [23] [24] Because of the clinical relevance of myeloma bone disease, we hypothesized that the bone resorption marker ICTP may add to the prognostic value of ISS. Thus, we evaluated the adverse prognostic impact of ICTP in combination with established prognostic factors in a patient cohort of 100 consecutive newly diagnosed patients with symptomatic MM.
Materials and methods

Patients
Serum samples and clinical data from 100 patients with newly diagnosed, symptomatic MM were collected at two study centers at the university hospitals in Berlin and Ulm between 1999 and 2005. The patients were classified as symptomatic MM, according to the International Myeloma Working Group criteria. 25 Patient data and samples were accessed after informed consent, following local institutional review board requirements and in accordance with the Declaration of Helsinki. Peripheral blood was processed immediately by centrifugation at 1500 g for 10 min, and serum samples were stored at À76 1C. Demographics and disease characteristics of the 100 patients with symptomatic MM, who had indications for systemic treatment, are shown in Table 1 . Patients with symptomatic MM, who received previous chemotherapy or radiation before presentation at study center, were not included in this study. Fifty-five patients received high-dose therapy (HDT) with melphalan 200 mg/m 2 (n ¼ 46) or melphalan 140 mg/m 2 (n ¼ 9). Forty-five patients ineligible for HDT received conventional dose chemotherapy. Conventional dose treatment regimens were melphalan/prednisone (n ¼ 28), doxorubicin/dexamethasone (n ¼ 11), oral idarubicin/dexamethasone (n ¼ 2), bendamustine/prednisone (n ¼ 1), dexamethasone monotherapy (n ¼ 2) or thalidomide/dexamethasone (n ¼ 1). Survival status and date of last follow-up were recorded until November 2007.
In 100 patients with symptomatic MM, ICTP levels were correlated with the extent (none versus 1-3 versus 43) of lytic bone lesions detected by conventional radiography. In addition, we compared ICTP levels in 100 patients with symptomatic MM versus 40 patients with smoldering MM versus 20 patients with monoclonal gammopathies of undetermined significance.
ICTP immunoassay
Serum ICTP was measured by a competitive radioimmunoassay (Orion Diagnostica, Espoo, Finland) using I 125 -labelled ICTP as tracer molecule and a polyclonal rabbit antiserum as detection reagent. The upper reference limit for healthy controls was 5.0 mg/l for female and 5.2 mg/l for male individuals as evaluated in the local clinical chemistry laboratory. There was no correlation between age and ICTP levels in healthy individuals. The intra-and interassay concentration variants tested in a series of repetitive samples were 1 and 11% respectively, which were within the range given by the manufacturer. The assay controls supplied by the manufacturers were within the range of mean ± 2 s.d. The assay is commercially available as a radioimmunoassay or as an enzyme-linked immunoassay, and is validated for automated processing in routine clinical chemistry laboratories. The costs are around 20$ per test.
Prognostic factors
Serum ICTP was included in the survival analysis using the upper reference limit (5.0 mg/l for female and 5.2 mg/l for male individuals) as a cutoff value. In addition to ICTP, the prognostic factors albumin and b2M were evaluated, using previously established cutoff values (albumin: X versus o3.5 g/dl; b2M: o versus X3.5 mg/l) to dichotomize risk groups for survival analysis. ISS was calculated from albumin and b2M according to the cutoff values given in the original publication.
11 Bone marrow plasma cell infiltration at a cutoff level of 33%, 11 del(13q14) 6, 26 and type of treatment (HDT versus conventional dose chemotherapy) 27 were evaluated in a univariate and multivariate survival analysis. Albumin and b2M levels were measured in our central clinical chemistry laboratories. As conventional cytogenetics could not be performed due to lack of metaphases in the majority of the patients, we analyzed chromosomal deletion 13q14 by interphase fluorescence in situ hybridization using Vysis LSI 13 (RB-1) probe (Vysis Inc., Des Plaines, IL, USA), as described previously. 28 
Statistical analysis
Comparisons of ICTP serum levels between the independent groups of patients with monoclonal gammopathies of undetermined significance versus smoldering MM versus symptomatic MM were calculated by the Kruskal-Wallis test. Mann-Whitney U or Kruskal-Wallis test was applied for comparison of ICTP values in patients with versus without lytic bone lesions or in patients with no versus 1-3 versus 43 lytic lesions, respectively. In 100 patients with symptomatic MM, prognostic parameters for OS were analyzed. Survival time was calculated from the date of primary diagnosis of symptomatic MM to the date of disease-related death. The univariate survival analysis was performed by the Kaplan-Meier method combined with logrank test. Variables found to be statistically significant at the Po0.05 level were entered into a multivariate Cox proportional hazards regression analysis 29 with a backward-stepping exclusion to identify the most significant model. We calculated two adjusted models: model A included albumin, b2M, ICTP, HDT, del(13q14) and model B consisted of ISS (instead of separately included variables albumin and b2M), ICTP, HDT and del(13q14).
Using the results of the multivariate analysis, parameters were ranked by hazard ratio, and the most powerful prognostic factors were incorporated into a prognostic score together with the ISS parameters albumin and b2M. The calculations were performed with the SPSS Software version 14.0 (SPSS Inc., USA). For all test In the univariate Kaplan-Meier analysis, six parameters were significant prognostic factors for OS in newly diagnosed symptomatic MM (Table 2) : ICTP (survival rate at 5 years: 90 versus 39%, log-rank: Po0.001, Figure 1 ), b2M (5-year OS: 75 versus 41%, log-rank: P ¼ 0.005), albumin (5-year OS: 64 versus 43%, log-rank: P ¼ 0.015), ISS (5-year OS: 72 versus 62 versus 35%, log-rank: P ¼ 0.026, Figure 3a) , HDT (5-year OS: 69 versus 45%, log-rank: Po0.001) and del(13q14) (5-year OS: 66 versus 46%, log-rank: P ¼ 0.043). There was a trend toward poor prognosis for patients with high bone marrow plasma cell infiltration greater than 33%, but bone marrow plasma cell infiltration did not reach statistical significance for OS (P ¼ 0.073). Lytic bone lesions, as categorized into two variables (absence versus presence of lytic lesions) or into three variables (none versus 1-3 versus 43 lytic lesions), were not significant prognostic factors for OS in the univariate analysis (P ¼ 0.289 and P ¼ 0.291, respectively). Results of univariate and multivariate survival analysis are summarized in Table 2 . In the multivariate Cox regression analysis, serum ICTP and HDT were the most powerful prognostic factors (Po0.001 for both), with a ninefold (hazard ratio: 9.17) risk in patients with elevated ICTP and a sixfold risk reduction (hazard ratio: 0.18) for patients receiving HDT. Further prognostic parameters, which remained in the final model after stepwise exclusion, were b2M (P ¼ 0.012, hazard ratio: 2.80) and del(13q14) (P ¼ 0.015, hazard ratio: 2.49). Albumin was excluded after the first backward step from the albumin and b2M adjusted model A (containing albumin, b2M, ICTP, HDT, del(13q14)), and ISS was excluded after the first step from the ISS-adjusted model B (containing ISS, ICTP, HDT, del(13q14)). Elevated serum ICTP was an adverse prognostic factor in each ISS group (Table 3) . In each ISS stage, the two subgroups of patients with normal versus elevated ICTP had a significantly different OS (ISS I: P ¼ 0.027; ISS II: P ¼ 0.022 and ISS III: P ¼ 0.013) (Figures 2a-c) . Five-year OS rates were 94 versus 50% in ISS I (Figure 2a) , 100 versus 47% in ISS II (Figure 2b ) and 76 versus 22% in ISS III (Figure 2c) . A prognostic score, including the risk factors ICTP (4 normal value), albumin (o3.5 g/dl) and b2M (X3.5 mg/l), was formed to define four risk groups with no, one, two or three risk factors. This combined ISS-ICTP score clearly separated four prognostic groups (log-rank: Po0.001) with 5-year OS rates of 95, 64, 46 and 32%, respectively (Figure 3b ). Compared to ISS (Table 4) , this scoring system identifies an additional very-low risk group (ICTP pnormal value, albuminX3.5, b2Mo3.5) with a 5-year OS rate of 95%. In this very-low risk group, we found no significant survival benefit for HDT (P ¼ 0.24), whereas HDT was a favorable prognostic factor in our risk groups 1-3 Table 2 Univariate and multivariate prognostic significance of ICTP, b2M, albumin, del(13q14), HDT and BMPC infiltration in patients with newly diagnosed symptomatic MM.
Parameter
Univariate analysis (log-rank) Multivariate analysis (Cox regression)
P-value
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) (P ¼ 0.037, P ¼ 0.011 and P ¼ 0.012) and in ISS stages I-III (P ¼ 0.026, P ¼ 0.001 and P ¼ 0.052).
Discussion
In the last 20 years, various risk factors were evaluated to improve the prognostic information in patients with MM, as the identification of novel prognostic factors is critical for our understanding of myeloma biology, characterization of risk groups and optimizing patient treatment. 30, 31 Particularly, b2M was widely recognized to have a strong prognostic impact in different models. 3, 32 Recently, the ISS staging system was presented as a simple prognostic score, based on the two parameters serum b2M and albumin, which significantly separates three risk groups in symptomatic MM. 11 As there is emerging progress in understanding the biology of myeloma, there are efforts to predict the highly variable outcome of myeloma patients more accurately by evaluating novel Table 3 Adverse prognostic impact of ICTP in ISS stages I-III n 5-year OS (%) P ¼ (log-rank) Hazard ratio (95% CI) parameters that are more intrinsic to the biology of myeloma. 31 It was shown that combining b2M with the number of S-phase plasma cells 5 provided improved prognostic stratification, but the method has limitations due to its technical complexity and availability. The impact of cytogenetic and genomic changes was shown, particularly in patients receiving HDT. However, even in genetically defined subgroups, a heterogeneity in outcome is observed, suggesting the role of other prognostic factors. Evaluation of b2M leads to controversial results in distinguishing within the cytogenetic risk groups t(4;14). 33, 34 Our data confirm the prognostic validity of the ISS and the high prognostic impact of b2M and HDT in MM. Furthermore, here we demonstrate the adverse prognostic impact of the bone resorption marker ICTP in newly diagnosed, symptomatic MM in univariate and multivariate models for OS. ICTP separated two subgroups within every ISS stage with significantly different OS.
Carboxy-terminal telopeptide of type-1 collagen is a surrogate marker for collagen degradation with a high specificity for cancer-induced bone resorption activity. 35 Furthermore, ICTP has been identified as a prognostic factor in MM patients, 15, 16, 18 which is now confirmed in this study in univariate and multivariate models in patients with newly diagnosed symptomatic MM. Notably ICTP, but not the presence or absence of lytic bone lesions, was a significant prognostic factor for survival. This confirms previous observations that ICTP may reflect myeloma bone disease more accurately than conventional radiography alone. 15, 17 Because of the crucial role of increased bone resorption activity in the pathophysiology of MM 36, 37 and the strong statistic power of ICTP in multivariate models, ICTP should be considered to be incorporated in existing prognostic models. As standardization, broad availability and cost efficacy are basic requirements for a widely adopted staging system, we incorporated the serum parameters albumin, b2M and ICTP into a simple model, which defines four risk groups (0-3 risk factors) with significantly different OS in newly diagnosed symptomatic MM. This combined ISS-ICTP model adds to the prognostic accuracy of ISS, as the ISS-ICTP score identified four risk groups that largely differ in OS and stratifies risk groups more clearly than the ISS alone. We identified a very-low risk group, which had no risk factor, and achieved a 5-year OS rate of 95%. In this very-low risk group (group 0), in contrast to the groups 1-3 and ISS stages I-III, HDT was not associated with a survival benefit. Furthermore, the high-risk group 3 has an even worse median survival than in the ISS III stage (24 versus 44 months, respectively). It should be noted that there are differences between the ISS cohort 11 and our patient cohort, particularly concerning the spectrum and efficacy of first-line and post-relapse therapies. The ISS cohort comprises a time period from 1981 to 2002. The proportion of patients who received HDT was 35% (2807/7920), whereas our cohort comprises the years 1999-2005, and 55% of the patients received HDT. Moreover in our cohort, the majority of patients who developed refractory or relapsed disease received novel agents, such as immunmodulatory drugs or bortezomib. As the impact of prognostic factors is modulated by therapy, the prognostic impact of ICTP should be confirmed in a large study cohort treated with novel antimyeloma therapies. At the beginning of our study, t(4;14) or del(17pÀ) was not established ICTP and ISS in multiple myeloma C Jakob et al as parameter of poor prognosis in MM, but these factors should be included in risk analysis in future studies. The identification of a very-low risk group by low ICTP, low b2M and albumin43.5 mg/dl, which has no benefit from HDT, could have a clinical impact for selection of frontline therapy approaches, particularly in the era of novel agents. 38 
